✦ LIBER ✦

Compressing drug development timelines in oncology using phase '0' trials

✍ Scribed by Kummar, Shivaani; Kinders, Robert; Rubinstein, Larry; Parchment, Ralph E.; Murgo, Anthony J.; Collins, Jerry; Pickeral, Oxana; Low, Jennifer; Steinberg, Seth M.; Gutierrez, Martin

Book ID: 109947800
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 329 KB
Volume: 7
Category: Article
ISSN: 1474-1776
DOI: 10.1038/nrc2066

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 0 clinical trials in oncology: a p

Phase 0 clinical trials in oncology: a paradigm shift for early drug development?

✍ Chris H. Takimoto 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 271 KB

13 INVITED Phase zero clinical-trials in

13 INVITED Phase zero clinical-trials in oncology: a new paradigm for early drug development?

✍ C.H. Takimoto 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 52 KB

The impact of FDA and EMEA guidelines on

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials

✍ Marchetti, S; Schellens, J H M 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB

Predicting the Outcome of Phase III Tria

Predicting the Outcome of Phase III Trials using Phase II Data: A Case Study of Clinical Trial Simulation in Late Stage Drug Development

✍ Filip De Ridder 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Differences between a drug regimen emplo

Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice : A note of caution

✍ Maurie Markman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

It is reasonable to assume that a decision to permit wider access to new anticancer agents after the completion of only phase 1 trials will almost certainly result in the administration of such therapy to a substantial population of individuals who would not have been eligible for such “registration